Intuitive Surgical, Inc.
ISRGHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeIntuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The $146.01B market capitalization puts ISRG squarely in large-cap range for its industry. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung.
Market Cap
$146.01B
Beta
1.51
P/E (TTM)
49.97
P/E (Fwd)
34.96
EPS (TTM)
$8.25
EPS (Fwd)
$11.79
ROE
17.2%
ROA
10.2%
Cash
$4.52B
Total Debt
$0
Free CF
$2.25B
52W Change
-25.3%
Annual Financials
Cash vs Debt
Intuitive Surgical, Inc. reports $4.52B in cash and $0 in total debt. Annual free cash flow of $2.25B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 17.2%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 10.2% further supports the picture of efficient asset utilization. Revenue has grown from $6.22B (2022) to $10.06B (2025), reflecting a 62% increase over the period.
Intuitive Surgical, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Intuitive Surgical, Inc. and its sector.